Clinical Trial Update: uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung [Phase 2]

View source ↗

Summary

Clinical trial update describing Phase 2 evaluation of uPAR-PET imaging as a prognostic tool in patients with Non-small cell lung cancer, malignant pleural meso…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Large Cell Neuroendocrine Carcinoma of the Lung
• Malignant Pleural Mesothelioma
• Non-small Cell Lung Cancer

Snippet

Sponsor: Rigshospitalet, Denmark | Conditions: Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma | Phase 2 | Status: UNKNOWN